ROME (ITALPRESS) – Johnson & Johnson will delay the distribution of its vaccine against Covid-19 in Europe after the US authorities have decided to suspend its use. “The safety and well-being of the people using our products are our top priority. We are aware of an extremely rare disorder that has led to the formation of blood clots in combination with low platelets in a small number of people who have received our vaccine against COVID-19 – reads a note from the pharmaceutical company -. The US Centers for Disease Control (CDC) and the Food and Drug Administration (FDA) are examining data on six cases reported in the States United on over 6.8 million doses administered. For reasons of utmost caution, the CDC and the FDA have recommended a pause in the use of our vaccine. ” “In addition, we are investigating these cases with the European health authorities. We have taken the decision to proactively delay the launch of our vaccine in Europe – the note continues -. We are working closely with medical experts and health authorities, and we strongly encourage communication. This information is open to healthcare professionals and the public. The CDC and the FDA have made information available on the proper recognition and management of these disorders due to the unique treatment required by this type of blood clot. Health authorities advise people who have received our COVID-19 vaccine and develop severe headache, abdominal pain, leg pain or shortness of breath within three weeks of vaccination to contact their doctor. ” (ITALPRESS). col / sat / red 13-Apr-21 17:09
COPYRIGHT today © breaking latest news